Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.

Byonanebye, Dathan M; Polizzotto, Mark N; Neesgaard, Bastian; Sarcletti, Mario; Matulionyte, Raimonda; Braun, Dominique L; Castagna, Antonella; de Wit, Stéphane; Wit, Ferdinand; Fontas, Eric; Vehreschild, Jörg Janne; Vesterbacka, Jan; Greenberg, Lauren; Hatleberg, Camilla; Garges, Harmony; Gallant, Joel; Volny Anne, Alain; Öllinger, Angela; Mozer-Lisewska, Iwona; Surial, Bernard; ... (2022). Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. HIV medicine, 23(8), pp. 895-910. Wiley 10.1111/hiv.13273

[img]
Preview
Text
HIV_Medicine_-_2022_-_Byonanebye_-_Incidence_of_hypertension_in_people_with_HIV_who_are_treated_with_integrase_inhibitors.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (298kB) | Preview

OBJECTIVE

To compare the incidence of hypertension in people living with HIV receiving integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or boosted protease inhibitors (PIs) in the RESPOND consortium of HIV cohorts.

METHODS

Eligible people with HIV were aged ≥18 years who initiated a new three-drug ART regimen for the first time (baseline), did not have hypertension, and had at least two follow-up blood pressure (BP) measurements. Hypertension was defined as two consecutive systolic BP measurements ≥140 mmHg and/or diastolic BP ≥90 mmHg or initiation of antihypertensives. Multivariable Poisson regression was used to determine adjusted incidence rate ratios (aIRRs) of hypertension, overall and in those who were ART naïve or experienced at baseline.

RESULTS

Overall, 4606 people living with HIV were eligible (INSTIs 3164, NNRTIs 807, PIs 635). The median baseline systolic BP, diastolic BP, and age were 120 (interquartile range [IQR] 113-130) mmHg, 78 (70-82) mmHg, and 43 (34-50) years, respectively. Over 8380.4 person-years (median follow-up 1.5 [IQR 1.0-2.7] years), 1058 (23.0%) participants developed hypertension (incidence rate 126.2/1000 person-years, 95% confidence interval [CI] 118.9-134.1). Participants receiving INSTIs had a higher incidence of hypertension than those receiving NNRTIs (aIRR 1.76; 95% CI 1.47-2.11), whereas the incidence was no different in those receiving PIs (aIRR 1.07; 95% CI 0.89-1.29). The results were similar when the analysis was stratified by ART status at baseline.

CONCLUSION

Although unmeasured confounding and channelling bias cannot be excluded, INSTIs were associated with a higher incidence of hypertension than were NNRTIs, but rates were similar to those of PIs overall, in ART-naïve and ART-experienced participants within RESPOND.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Surial, Bernard

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1468-1293

Publisher:

Wiley

Language:

English

Submitter:

Pubmed Import

Date Deposited:

03 Mar 2022 09:41

Last Modified:

05 Dec 2022 16:12

Publisher DOI:

10.1111/hiv.13273

PubMed ID:

35233903

Uncontrolled Keywords:

HIV antiretroviral agents hypertension integrase inhibitors

BORIS DOI:

10.48350/166316

URI:

https://boris.unibe.ch/id/eprint/166316

Actions (login required)

Edit item Edit item
Provide Feedback